Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

Literature DB >> 26270860

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

Natsuko Matsumura¹, Mikio Ohtsuka, Nobuyuki Kikuchi, Toshiyuki Yamamoto.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2016 PMID： 26270860 DOI： 10.2340/00015555-2212

Source DB: PubMed Journal: Acta Derm Venereol ISSN： 0001-5555 Impact factor: 4.437

Keyword Cloud
Cited

× No keyword cloud information.

26 in total

1. Combining immunotherapy and natural immune stimulants: mechanisms and clinical implications.

Authors: Khara Lucius; Jacob Hill
Journal: J Cancer Res Clin Oncol Date: 2019-01-23 Impact factor: 4.553

2. Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Authors: Emilie Bousquet; Allison Zarbo; Emilie Tournier; Christine Chevreau; Julien Mazieres; Mario E Lacouture; Vincent Sibaud
Journal: Acta Derm Venereol Date: 2017-04-06 Impact factor: 4.437

Review 3. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

4. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Authors: Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube
Journal: Am J Surg Pathol Date: 2017-10 Impact factor: 6.394

5. Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis.

Authors: Anju George; Renu George
Journal: Indian Dermatol Online J Date: 2020-03-09

6. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

Authors: Vasiliki Nikolaou; D Voudouri; G Tsironis; A Charpidou; G Stamoulis; I Triantafyllopoulou; I Panoutsopoulou; E Xidakis; A Bamias; E Samantas; G Aravantinos; H Gogas; D Rigopoulos; K Syrigos; A Stratigos
Journal: Support Care Cancer Date: 2019-03-27 Impact factor: 3.603

Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

1. Combining immunotherapy and natural immune stimulants: mechanisms and clinical implications.

2. Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Review 3. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

4. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

5. Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis.

6. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

Review 7. The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

8. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].

Review 9. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Review 10. Immune checkpoint inhibitor-related dermatologic adverse events.